These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 9096194)
21. In vitro activity of difloxacin against canine bacterial isolates. van den Hoven R; Wagenaar JA; Walker RD J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834 [TBL] [Abstract][Full Text] [Related]
22. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients. Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478 [TBL] [Abstract][Full Text] [Related]
23. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001]. Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872 [TBL] [Abstract][Full Text] [Related]
24. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Richard P; Delangle MH; Raffi F; Espaze E; Richet H Clin Infect Dis; 2001 Jan; 32(1):162-6. PubMed ID: 11112677 [TBL] [Abstract][Full Text] [Related]
25. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection]. Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068 [TBL] [Abstract][Full Text] [Related]
26. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia. Qadri SM; Abo-Askar H; Ueno Y Chemotherapy; 1992; 38(2):92-8. PubMed ID: 1317281 [TBL] [Abstract][Full Text] [Related]
27. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Rolston KV; Nguyen H; Messer M; LeBlanc B; Ho DH; Bodey GP Antimicrob Agents Chemother; 1990 Nov; 34(11):2263-6. PubMed ID: 2127348 [TBL] [Abstract][Full Text] [Related]
28. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375 [TBL] [Abstract][Full Text] [Related]
29. Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria. John JF; Twitty JA Antimicrob Agents Chemother; 1984 Nov; 26(5):781-4. PubMed ID: 6440481 [TBL] [Abstract][Full Text] [Related]
30. Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria. Heisig P; Wiedemann B Antimicrob Agents Chemother; 1991 Oct; 35(10):2031-6. PubMed ID: 1759823 [TBL] [Abstract][Full Text] [Related]
31. [Effect of a ticarcillin-clavulanic acid (timentin) combination on bacteria resistant to ticarcillin]. Rouhan D; Le Noc P; Robert J Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):461-5. PubMed ID: 3937121 [TBL] [Abstract][Full Text] [Related]
32. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones. Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386 [TBL] [Abstract][Full Text] [Related]
33. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). III. Secular changes in susceptibility]. Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H Jpn J Antibiot; 1995 Sep; 48(9):1174-263. PubMed ID: 7474335 [TBL] [Abstract][Full Text] [Related]
34. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens]. Smirnova LB; Sokolova VI Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102 [TBL] [Abstract][Full Text] [Related]
35. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177 [TBL] [Abstract][Full Text] [Related]
36. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. Hoogkamp-Korstanje JA J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498 [TBL] [Abstract][Full Text] [Related]
37. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Sader HS; Farrell DJ; Flamm RK; Jones RN J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763 [TBL] [Abstract][Full Text] [Related]
38. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients. Rolston KV; Ho DH; LeBlanc B; Bodey GP Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of 500 gram negative isolates to determine the number of major susceptibility interpretation discrepancies between the Vitek and MicroScan Walkaway for 9 antimicrobial agents. Rittenhouse SF; Miller LA; Utrup LJ; Poupard JA Diagn Microbiol Infect Dis; 1996 Sep; 26(1):1-6. PubMed ID: 8950521 [TBL] [Abstract][Full Text] [Related]
40. [Effect of efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine to MIC values of ciprofloxacin in ciprofloxacin resistant gram-negative bacteria]. Coban AY; Bayram Z; Sezgin FM; Durupinar B Mikrobiyol Bul; 2009 Jul; 43(3):457-61. PubMed ID: 19795621 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]